glp 1 and gip dual agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Polyagonists Enable Increasingly Effective Treatment
Description
Cells were seeded in 96-well plates at a density of 35,000 cells per well and transiently transfected using Lipofectamine 2000 according to the manufacturers protocol
Antagonizing GIPR adds fire to the GLP-1R flame
Animal venoms have proven to be among natures most sophisticated pharmacological librariesmolecular arsenals honed by evolution for predation and defense that often target precisely the same receptors and channels that interest drug developers
Several of these drugs (exenatide (Byetta and Bydureon), liraglutide (Victoza for diabetes, Saxenda for obesity) albiglutide (Tanzeum), dulaglutide (Trulicity), and lixisenatide (Lyxumia in Europe, Adlyxin in the United States) have been around for at least ten years
Notably, the effect size was very marginal, akin to the negative findings reported in our study [43]
soi: 10.1056/nejmoa2505669
